Stenting of de-novo lesions on unprotected left main coronary artery: Results of a five-year follow-up period  by Pache, Jürgen et al.
JACC March 19,2003 
POSTER SESSION 
1052 Clinical Results With Coronary Stents 
Sunday, March 30,2003,3:00 p.m.-5:OO p.m. 
McCormick Place, Hall A 
Presentation Hour: 3:00 p.m.-4:OO p.m. 
1052-l 78 Accelerated Transplant Vasculopathy Portends 
Proliferative Restenosis After Percutaneous Coronary 
Intervention in Cardiac Transplant Patients 
John C. Wanq, Satyendra Giri, James C. Fang, Gilbert H. Mudge, Campbell Rogers, 
Brigham &Women’s Hospital, Boston, MA 
Background: Allograft vasculopathy (AV) after cardiac transplant (TX) causes diffuse 
concentric narrowing. Percutaneous intervention(PCI) is widely used in treating AV. We 
evaluated l-year clinical and quantitative angiographic (QCA) results of PCI in TX pts. 
Methods: 432 pts underwent TX at Brigham &Women’s Hospital from Feb 1984 to Aug 
2001. Oi these, 24 (92% male, mean age 55 yrs) underwent PCI of 49 lesions. Core-lab 
QCA determined % diameter stenosis (LX?), reference (RD) and minimal lumen (MLD) 
diameters. Results: Procedural success was 98.0%. Of 24 pts, 5 (21%) died within l- 
year of PCI. QCA of 24 PCI lesions in 14 pts (74%) with l-year follow up revealed pre- 
procedure: (RD 2.61*0.23mm. MLD 0.39*0.28mm, % DS 85.1ill.O) and post proce- 
dure: (RD 2.74+0.25mm, MLD 2.27*0.38mm. % DS 17.6+8.9, acute gain 1.88+0.47mm). 
One year follow up showed(RD 2.59*0.22mm, MLD 1.25*0.80mm. % DS 52.0t29.6) a 
Late Loss (LL) of 1.02r0.82mm and loss index of 0.55iO.43. Restenosis (DS>50%) 
occurred in 11(46%) lesions. Seventeen matched AV lesions(DS 28.2y&l1.4) at a non- 
PCI site had a LL of 0.66+0.38mm. Pts with restenosis also had greater LL at the non- 
intervened matched site than patients without restenosis(0.94*0.36mm vs 
0.40*0.16mm, p=O.O03). Patient-specific LL at PCI and non-PC1 sites correlated signifi- 
cantly (r=O.65, p=O.OOl, figure) Conclusions: PCI in TX pts has high procedural suc- 
cess. Restenosis rates are high in pts with rapid progression of AV suggesting common 
mechanisms 
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1052-l 79 Stenting of de-Novo Lesions on Unprotected Left Main 
Coronary Artery: Results of a Five-Year Follow-Up 
Period 
JDroen Pache, Kambiz Rahbar, Julinda Mehilli, Josef Dirschlnger, Joerg Hausleiter, 
Helmut ScMhlen, Hildegard Bolwein, Adnan Kastrati, 1. Medizinische Klinik rechts der 
Isar, Munich, Germany, Deutsches Herzzentrum Muenchen, Munich, Germany 
Background: Surgical revascularlsation is the standard procedure in patients (pts) with 
unprotected left main disease (LMD). However, the increase use of stents, the improved 
operator experience and the results of several studies indicate high angiographic and 
clinical success rate after elective percutaneous coronary interventions. 
Methods: In a period of 3 years we analyzed a consecutive cohort of 69 pts undergoing 
stenting for LMD. Only pts with acute myocardial infarction or/and cardiogenic shock 
were excluded. All pts had successful LM stenting. Clinical adverse events, death of any 
cause, myocardial infarction and target vessel revascularization, were monitored over a 
period of 5 years. 
Results: Mean age was 71 t 12 years, 25 (36%) were women and 15 (22%) had diabe- 
tes. Two patients died within the first 30 days after the intervention (2.9%). Five-year 
overall suwival (84.7%) and survival free of adverse events (62.9%) are shown in figures 
l&2. Most of the adverse events consisted of reintewentions (21 .t3%) due to restenosis 
in the left main vessel or the ostia of the left anterior descending or left circumflex ader- 
ies. 
Conclusion: In high-volume interventional centers, stenting enables favorable short and 
long-term results considering the high-risk profile of patients with left main coronary 
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artery disease. These and previous results in the same category of patients reinforce the 
need of randomized clinical trials comparing bypass surgery with stenting in patients with 
left main disease. 
1052-l 80 Safety of Percutaneous Coronary Interventions Without 
On-Site Cardiac Surgery: A Recent 1 O-Year Experience 
of 5,909 Cases 
William K. Hui, Nick Gerning. PO Kee Cheung, Peter Klinke, Colleen Norris, Neil Brass, 
Royal Alexandra Hospital, Edmonton, AB, Canada 
In the past 10 years, stents and platelet Ilb/llla inhibitors(llbllla) have improved the safety 
and outcomes of percutaneous coronary interventions(PCls). These advances may be 
especially important in hospitals performing PCls without on-site cardiac surgery. 
The Royal Alexandra Hospital(RAH) has performed PCls without on-site cardiac surgery 
for over 20 years. Surgical support is provided at a regional centre 6 km away on a next 
available OR basis. Excellent rapport with cardiac surgeons was maintained through joint 
weekly rounds. At RAH. stents were introduced in 1993 and llbllla in 1997. From 1992. 
2001, 5,909 PCls(7,440 lesions) were performed. Overall lesion success was 94.8% and 
major complication rate was 1.4%(death 0.6%. Ml 0.5%, emergency bypass 0.3%) 
including cardiogenic shock patients. No patient died before emergency bypass or perio- 
peratively. Over the lo-year period, there was a significant rise in patient acuity urgency 
and ad hoc procedures. This was counterbalanced by an increase in the use of stents, 
llbllla and in operator case expenence. with significant improvement in success and 
decrease in major complication rates(see table). 
Our results showed that with good operator experience, rappod with cardiac surgeons, 
and the use of stents and Ilbllla, PCls can be performed safely with high success rates 
and very low complication rates without on-site cardiac surgery 
IO-Year PC1 Results (‘PC.01 YS 92-93,**P<.OOl vs 92.93,+P<.OOl vs 96.97) 
Year 92-93 94-95 96-97 96-99 00-01 
No. of PCls 453 767 944 1345 2400 
No. of Lesions 521 894 1136 1705 3104 
lnterventionallst Case ExperiencelYear 113 192 266 269 400 
Primary/Rescue PCI 10 53 104 109 138. 
CCS Class 4 Patients 32.9% 39.6% 68.1% 67.9% 66.1%‘. 
Ilb/llla Use n/a n/a 8.1% 23.0% 48.9%+ 
stent use 2.9% 19.4% 51.1% 71.4% 82.2%*’ 
Urgent/Emergency PCI 57.4% 68.4% 77.3% 78.3% 75.2%” 
Ad hoc PCI 47.7% 54.6% 53.9% 61.0% 72.4%“* 
Lesion Success 90.2% 90.8% 93.8% 93.9% 97.6%” 
Death/Ml/Emergency Bypass 2.4% 3.1% I .6% 1.4% 0.6%” 
1052-181 Late In-Stent Restenosis Occurring After 12 Months Is 
Common and the Predictors Are Similar to Early In- 
Stent Restenosis 
Daniel A. Canes Gary S. Mints, Vivek M. Shah, Sue Apple, Neil J. Weissman, 
Washington Hospital Center, Washington, DC 
BackgroundJn-stent restenosis (ISR) is thought to end by 12 months. Restenosis after 
this period has not been described. 
Methods: From our clinical and intravascular ultrasound (IVUS) core laboratory data- 
bases we identified patients with native coronary stent procedures who returned to this 
institution with in-stent restenosis. 
Results: From 621 cases of in-stent restenosis, we identified 333 (53.62 %) with early 
ISR (<6months), 167(26.89%)with ISR between 6-12 months and 121 (19.48%) with late 
ISR (L 1 Pmonths). There was no Uiflerence in demographics between the groups, includ- 
ing frequency of diabetes (34.2%, 25.7%, 36.4%). Lesion characteristics were also simi- 
lar, ostial lesions (7.6%. 8.2%. 12.5%) and vessel size mm(2.77 +/- 0.64, 2.83 +/- .70 , 
2.84 +I- .60). In order to further study the patients with late ISR, we performed volumetric 
analysis on a subset of late ISR cases compared to early ISR cases. We examined the 
plaque morphology and consistency, stent volume, and the percent of plaque volume 
within the stent volume. When comparing early to late ISR IVUS did not detect any quali- 
tative or quantitative difference. 
